UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report

UroGen Pharma (URGN) “commended” the Bladder Cancer Advocacy Network, BCAN, on its release of The New Faces of Bladder Cancer Report. The survey found that nearly 80% of respondents reported fear of recurrence, rising to more than 90% among patients under 50. Among women, 86% reported fear of recurrence, and among patients who retained their bladder, 87% reported ongoing concern. The report also documents the cumulative procedural burden associated with bladder cancer management, with a substantial proportion of patients reporting five or more cystoscopies and some experiencing more than 15 procedures over the course of their disease. “These findings reinforce what patients and clinicians experience every day – bladder cancer is often a chronic condition defined by recurrence, repeated procedures, and persistent uncertainty,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “When patients face years of surveillance and intervention, treatment discussions must consider not only tumor control but also long-term quality of life, personal priorities, and emotional burden. Elevating the patient voice through data of this scale is critical to improving care.”